Ascletis Pharma Inc. Reports ASC37 Half-Life 6-Fold Longer Than Retatrutide

What happened

Ascletis Pharma reported poster presentations on obesity candidates ASC48 and ASC37. The ASC37 abstract says its half-life was six times longer than retatrutide in non-human primates and it produced marked weight loss in diet-induced obese mice; no human results were reported.

Confirmed

Global impact / market context

A longer half-life could mean ASC37 remains in the body longer, potentially shaping how often a future treatment is given. If that translates into people, longer drug exposure could influence dosing and development costs, but the mouse result does not establish patient benefit or commercial potential.

Analyst inference

This is preclinical evidence, meaning results come from animal studies rather than people. It adds an early data point to Ascletis’s obesity research, but the article gives no clinical trial findings, quantified weight-loss amount, or evidence that ASC37 can compete with established treatments.

Analyst inference

What to watch

1. Watch for fuller poster data on ASC37, including the size and duration of weight loss in mice and the methods used to compare its half-life with retatrutide. Analyst inference
2. Watch for announcements of human studies; results in people would help establish whether the longer half-life and animal weight-loss findings translate into a useful treatment. Analyst inference
3. Track whether Ascletis reports further development of ASC48 or ASC37, since the article confirms poster presentations but provides no next study dates or plans. Analyst inference

Evidence

• Original source link unavailable